Comparative Pharmacology
Head-to-head clinical analysis: AMEN versus NORETHINDRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMEN versus NORETHINDRONE.
AMEN vs NORETHINDRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory endometrium, inhibits gonadotropin release, and alters cervical mucus.
Norethindrone is a synthetic progestin that binds to progesterone receptors, suppressing gonadotropin (LH and FSH) release from the pituitary, inhibiting ovulation, and inducing secretory changes in the endometrium. It also has weak androgenic and estrogenic activity.
Medroxyprogesterone acetate (AMEN): 5-10 mg orally once daily for 5-10 days, starting on day 16 or 21 of menstrual cycle; also 150 mg IM every 3 months for contraception.
5 mg orally once daily for 5 days starting on day 5 of menstrual cycle or 0.35 mg orally once daily for contraception.
None Documented
None Documented
Terminal elimination half-life is approximately 4-6 hours. In severe hepatic impairment, half-life may be prolonged up to 12 hours.
Terminal elimination half-life: 5-14 hours (mean 8-10 hours); clinical context: requires once-daily dosing for steady state after ~2 days (5 half-lives).
Primarily hepatic metabolism to inactive metabolites, with <1% excreted unchanged in urine. Fecal elimination of metabolites accounts for ~30%.
Renal (30-50% as glucuronide conjugates, 5-10% unchanged), fecal (<10%)
Category C
Category D/X
Progestin
Progestin